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Abstract
Introduction: The objective was to investigate the potential implication of the IL18 gene promoter polymorphisms
in the susceptibility to giant-cell arteritis (GCA).
Methods: In total, 212 patients diagnosed with biopsy-proven GCA were included in this study. DNA from patients
and matched controls was obtained from peripheral blood. Samples were genotyped for the IL18-137 G>C
(rs187238), the IL18-607 C>A (rs1946518), and the IL18-1297 T>C (rs360719) gene polymorphisms with polymerase
chain reaction, by using a predesigned TaqMan allele discrimination assay.
Results: No significant association between the IL18-137 G>C polymorphism and GCA was found. However, the IL18
-607 allele A was significantly increased in GCA patients compared with controls (47.8% versus 40.9% in patients and
controls respectively; P = 0.02; OR, 1.32; 95% CI, 1.04 to 1.69). It was due to an increased frequency of homozygosity for
the IL18 -607 A/A genotype in patients with GCA (20.4%) compared with controls (13.4%) (IL18 -607 A/A versus IL18 -
607 A/C plus IL18 -607 C/C genotypes: P = 0.04; OR, 1.59; 95% CI, 1.02 to 2.46). Also, the IL18-1297 allele C was
significantly increased in GCA patients (30.7%) compared with controls (23.0%) (P = 0.003; OR, 1.48; 95% CI, 1.13 to 1.95).
In this regard, an increased susceptibility to GCA was observed in individuals carrying the IL18-1297 C/C or the IL18-1297
C/T genotypes compared with those carrying the IL18-1297 T/T genotype (IL18-1297 C/C plus IL18-1297 T/C versus IL18-
1297 T/T genotype in GCA patients compared with controls: P = 0.005; OR, 1.61; 95% CI, 1.15 to 2.25). We also found an
additive effect of the IL18 -1297 and -607 polymorphisms with TLR4 Asp299Gly polymorphism. The OR for GCA was
1.95 for combinations of genotypes with one or two risk alleles, whereas carriers of three or more risk alleles have an
OR of 3.7.
Conclusions: Our results show for the first time an implication of IL18 gene-promoter polymorphisms in the
susceptibility to biopsy-proven GCA. In addition, an additive effect between the associated IL18 and TLR4 genetic
variants was observed.
Introduction
Giant cell, arteritis (GCA) is a large- and medium-sized
blood vessel systemic vasculitis characterized by the
granulomatous involvement of the aorta and especially
its cranial branches [1]. GCA is now considered the
most common systemic vasculitis in elderly individuals
from Western countries [2,3]. Dendritic cells localized at
the adventitia-media border of normal medium-sized
arteries play a critical role in the initiation of this vascu-
litis [4]. The inflammatory activity of vascular lesions in
GCA is mediated by adaptive immune responses, with
CD4 T cells undergoing clonal expansion in the vessel
wall and releasing interferon (IFN)-g [4]. In the experi-
mental mouse model of GCA, systemic administration
of ligands for Toll-like receptor (TLR)2 or TLR4 in
human artery-SCID chimeras led to differentiation of
adventitial dendritic cells into chemokine-producing
effector cells with high-level expression of both CD83
and CD86 and mediated T-cell recruitment through
release of interleukin (IL)-18 [4]. GCA is also known to
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cally involved in modulating the process of intimal
hyperplasia, leading to the severe ischemic complications
observed in this vasculitis [5]. Interestingly, IFN-g activ-
i t yi sp r o m o t e db yI L - 1 8 ,ap r o i n f l a m m a t o r yc y t o k i n e ,
member of the IL-1 cytokine family, which has been
shown to exert innate and acquired immune responses
[6,7]. IL-18 is expressed by a wide range of immune
cells [8] and can mediate both Th1 and Th2 driven
immune responses [9,10]. Of potential implication in
GCA, IL-18 in combination with IL-12, induces IFN-g
production in Th1 cells, B cells, and natural killer cells,
promoting Th1-type immune responses [11,12]. How-
ever, IL-18 may also stimulate Th2 immune responses
in the absence of IL-12 [13,14].
GCA is a complex polygenic disease [15]. Besides a
strong association of GCA with genes that lie within the
major histocompatibility complex (MHC) [16-21], many
other studies have shown the implication of genetic var-
iants in key components of immune and inflammatory
pathways in GCA susceptibility or clinical expression of
this vasculitis [21-34].
IL18 gene is located on chromosome 11q22.2-22.3
[35] and several polymorphisms within the IL18 promo-
ter gene have been associated with different inflamma-
tory and autoimmune diseases [36-43].
An important step forward in our understanding of
the pathogenesis of autoimmune diseases may be to
establish the presence of shared mechanisms that may
lead to a variety of very different complex autoimmune
diseases. Taking all these considerations together, in this
study we sought to establish the potential role of three
polymorphisms (-137, -607, -1297) within the promoter
of the IL18 gene in the susceptibility to biopsy-proven
GCA.
Materials and methods
Patients
In total, 212 patients diagnosed with biopsy-proven GCA
and 405 controls were included in this study. All of the
patients fulfilled the 1990 American College of Rheuma-
tology criteria for the classification of GCA [44]. Inclusion
criteria [45] and clinical features of the patient population
were described previously [46]. Also, definitions for speci-
fic features of the disease, such as polymyalgia rheumatica
(PMR), visual ischemic complications, or other severe
ischemic manifestations, have been previously described
[47,48]. In all cases, biopsy-proven GCA patients were
initially treated with prednisone, 40-60 mg/day, for 3 to 4
weeks. Methyl-prednisolone boluses (1 g daily for 3 days)
followed by 60-mg prednisone/day for 3 to 4 weeks were
used in most patients who had visual ischemic complica-
tions or strokes. The prednisone dose was progressively
tapered until discontinuation. Apart from visual complica-
tions or strokes that were irreversible in some cases, other
typical features of the disease such as headache, asthenia,
jaw claudication, or PMR improved after corticosteroid
therapy. A decrease of erythrocyte sedimentation rate was
observed in all cases after the onset of corticosteroid
therapy.
Patients and controls are Caucasians, with at least two
previous generations born in the corresponding regions,
and were included in this study after written informed
consent. We obtained approval for the study from the
local ethical committees.
IL18 polymorphisms selection
Several variations within the IL18 gene promoter region
are responsible for changes in the transcription rate
[49,50]. In the present study, we selected two functional
IL18 promoter polymorphisms (IL18 -137 and -607),
which were suggested to alter the IL18 promoter activ-
ity. To investigate further into genetic variants within
the IL18 promoter region, we observed in the database
[51] a variant in this region that could have a potential
role in IL-18 expression (IL18-1297 or rs360719). We
also studied this polymorphism based on the minor
allele frequency and its ability to bind the transcription
factor Oct-1. Location of the polymorphisms site was
based on the GenBank Accession Nos. [Genbank:
AB015961] and [Genbank:BC007461] as the reference
sequence. Interestingly, we recently confirmed that the
IL18-1297 gene polymorphism has a functional associa-
tion with systemic lupus erythematosus [52].
IL18 genotyping methods
DNA was obtained from peripheral blood mononuclear
cells, by using standard methods. The genotyping of the
three IL18 polymorphisms was performed by using pre-
designed TaqMan SNP Genotyping Assays (Applied Bio-
systems, Foster City, CA), as previously described [52].
Statistical analysis
We used the c
2 test for Hardy-Weinberg equilibrium
and statistical analysis to compare allelic and genotypic
distributions. Genotype distribution was assessed by
using the c
2 test. Odds ratio (ORs) and 95% confidence
intervals (95% CIs) were calculated according to Woolf’s
method by using the Statcalc program (Epi Info 2002;
Centers for Disease Control and Prevention, Atlanta,
GA, USA). P values < 0.05 were considered statistically
significant. LD was calculated by using Haploview v 4.0.
A logistic regression model was used to estimate gene-
gene interaction between the IL18 and TLR4 SNPs and
for the additive effects of the three SNPs. Fisher’s Exact
test was used to test for the difference in IL18 and
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Logistic regression analyses were performed by using
the software STATA (v.10.1).
Results
IL18 gene polymorphisms are associated with
susceptibility to GCA
The case/control ratio was 1:2, approximately. The esti-
mated power of this study for an estimated OR between
1.5 and 2.0 was 77% to 99.5%.
No evidence of departure from Hardy-Weinberg equi-
librium was observed in controls.
Table 1 shows the allele and genotype frequencies of
the IL18 -137 G>C, -607 C>A, and -1,297 T>C poly-
morphisms in biopsy-proven GCA patients and healthy
subjects.
No significant association between the IL18 -137 G>C
and GCA was observed. However, when the IL18 -607
C>A was assessed, we found that the frequency of allele
A was significantly increased in biopsy-proven GCA
patients compared with controls (47.8% versus 40.9%,
respectively; P = 0.02; OR, 1.32; 95% CI, 1.04-1.69). It
was due to a significantly increased frequency of homo-
zygosity for the IL18 -607 A/A genotype in the group of
patients with biopsy-proven GCA compared with
controls (20.4% versus 13.8 in patients and controls,
respectively; IL18 -607 A/A homozygous versus IL18
-607 C/A plus IL18 -607 C/C: P = 0.04; OR, 1.59; 95%
CI, 1.02-2.46) (Table 1).
Interestingly, a significant association between biopsy-
proven GCA and the IL18-1297 T>C was also found. In
this regard, the IL18-1297 allele C frequency was signifi-
cantly increased in biopsy-proven GCA patients (30.7%)
compared with controls (23.0%) (P = 0.003; OR, 1.48;
95% CI, 1.13-1.95) (Table 1). Moreover, the genotype
distribution of the IL18-1297 T>C polymorphism dis-
closed statistically significant differences between
biopsy-proven GCA patients and controls (P = 0.011). It
was due to a reduced frequency of individuals carrying
the IL18-1297 T/T genotype in the group of biopsy-pro-
ven GCA patients (46.7%) compared with the controls
(58.5%). In this regard, an increased susceptibility to
GCA was observed in individuals carrying the IL18-1297
C/C or the IL18-1297 C/T genotypes (IL18-1297 C/C)
plus T/C genotypes versus T/T genotype in GCA
patients compared with controls: P = 0.005; OR, 1.61;
95% CI, 1.15-2.25). We did not perform a haplotype
analysis because the most associated SNP rs360719
(-1297) is not located in a haplotype block, but is a
singleton.
Table 1 IL18 gene polymorphisms in a series of biopsy-proven GCA and matched controls
IL18
Polymorphisms
GCA patients
Number (%)
Healthy controls
Number (%)
-137 (G->C) (rs187238) Number = 212 Number = 403 P value OR (95% CI)
G/G 106 (50.0) 224 (55.6) Reference
-
G/C 94 (44.3) 159 (39.4) 0.20 1.25 (0.87-1.79)
C/C 12 (5.7) 20 (5.0) 0.53 1.27 (0.56-2.84)
G 306 (72.2) 607 (75.3) Reference
-
C 118 (27.8) 199 (24.7) 0.23 1.18 (0.89-1.55)
-607 (C->A) (rs1946518)
a Number = 212 Number = 405 P value OR (95% CI)
C/C 53 (24.9) 129 (31.9) Reference
-
C/A 116 (54.7) 220 (54.3) 0.21 1.28 (0.85-1.94)
A/A 43 (20.4) 56 (13.8) 0.02 1.87 (1.09-3.21)
C 221 (52.2) 478 (59.1) Reference
-
A 203 (47.8) 332 (40.9) 0.02 1.32 (1.04-1.69)
-1297 (T->C) (rs360719)
b Number = 212 Number = 405 P value OR (95% CI)
T/T 99 (46.7) 237 (58.5) Reference
-
T/C 96 (45.3) 150 (37.0) 0.02 1.53 (1.07-2.20)
C/C 17 (8.0) 18 (4.4) 0.02 2.26 (1.063-4.82)
T 294 (69.3) 624 (77.0) Reference
-
C 130 (30.7) 186 (23.0) 0.003 1.48 (1.13-1.95)
aGenotype distribution for the IL18 -607 (C->A) polymorphism: P = 0.054.
bGenotype distribution for the IL18 -1297 (T->C) (rs360719): P = 0.011.
Genotype frequencies for the IL18 -607 (C->A) (rs1946518) polymorphism: IL18 -607 A/A homozygous versus IL18 -607 C/A plus IL18 -607 C/C: P = 0.04; OR, 1.59;
95% CI, 1.02-2.46.
Genotype frequencies for the IL18-1297 (T->C) (rs360719) polymorphism: IL18-1297 C/C plus IL18-1297 T/C genotypes compared to IL18-1297 T/T genotype:
P = 0.005; OR, 1.61; 95% CI, 1.15-2.25.
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manifestation of GCA patients
In a further step, we stratified GCA patients according
to the presence of PMR, visual ischemic complications,
and severe ischemic manifestations. However, no signifi-
cant differences were observed when GCA patients
were compared according to the presence or absence of
these specific clinical features of the disease (data not
shown).
Additive effects of the IL18 and TLR4 risk alleles in GCA
We recently reported an association between the TLR4
Asp299Gly polymorphism and GCA in our population
[46]. In the present study, we investigated the potential
combined effect of the risk IL18 and TLR4 alleles on
GCA susceptibility by using an additive logistic regres-
sion model. The distribution of the different combina-
tions of IL18 and TLR4 risk alleles in GCA patients and
controls is shown in Additional file 1. The overall differ-
ence in risk allele counts between GCA patients and
controls was statistical significance, P =0 . 0 1 .W e
observed an additive effect of risk alleles on susceptibil-
ity to GCA. Figure 1 shows the OR for GCA according
to the presence of one or two and three or more risk
alleles among these three genetic variants, by using the
individuals with zero risk allele as the reference group.
A ss h o w ni nt h ef i g u r e ,t h er i s ko fG C Ai n c r e a s e sa sa
function of the number of risk alleles, in an additive
manner. Thus, the OR for GCA is 1.9 (CI, 1.1-2.3) for
carriers of one or two risk alleles, and 3.7 (CI, 1.9-7.2)
for carriers of three or more risk alleles.
Discussion
In the present study, we examined for the first time the
contribution of three polymorphisms in the promoter
region of the IL18 gene for the susceptibility to GCA.
Our results support a potential role of the IL18 -607
C>A (rs1946518) and the IL18-1297 T>C (rs360719)
gene polymorphisms in the predisposition to biopsy-
proven GCA. Individuals carrying the IL18 -607 A/A
showed an increased risk of having GCA compared with
controls. A protective effect against the development of
GCA was found in individuals carrying the IL18-1297
T/T genotype. In contrast, an increased risk of GCA
was observed in individuals carrying the IL18-1 2 9 7
allele C.
Proinflammatory cytokines play a major role in the
pathogenesis of GCA [53], a disease associated with a
high inflammatory response [54]. IL-18 is a proinflam-
matory cytokine that induces T-helper 1 differentiation
and has cytotoxic T-lymphocyte functions. IL-18 has
also emerged as a pivotal cytokine in different autoim-
mune diseases [55]. A number of functional polymorph-
isms within the proximal promoter of the IL18 gene
that may interfere with transcription-factor-binding sites
have been verified [49,50]. The implication of the IL18
-1297 T>C polymorphism in the susceptibility to GCA
also has functional relevance because recent data from
our group confirmed that the relative quantification of
mRNA performed in total RNA from 23 healthy indivi-
duals carrying different genotypes for IL18 -1297 T>C
(rs360719) polymorphism was associated with an
increased expression in individuals carrying the C allele
Figure 1 Combined effects of the risk alleles of (IL18 -607 and -1297) and TLR4 (Asp299Gly) on susceptibility to GCA. Linear regression
analysis showed an additive effect of the risk alleles of the IL18 and TLR4 on GCA susceptibility. The ORs with 95% CI are shown as a function of
number of risk alleles of GCA.
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reported and increased expression of IL18 in temporal
artery biopsies of GCA patients, with no correlation
with clinical manifestations or hematologic parameters.
All these data are in accordance with our results and
support a potential role of these gene variants in the
susceptibility to GCA but not in the phenotypic expres-
sion of this vasculitis.
It has been proposed that a variety of inflammatory
and autoimmune diseases may share common patho-
genic mechanisms. IL18 promoter gene polymorphisms
have been associated with several autoimmune diseases.
With respect to this, an association of the IL18 -137
G>C [rs187238] but not the IL18 -607 C>A (rs1946518)
gene polymorphism with susceptibility to type I diabetes
was reported in a study [39]. However, another study of
the same two promoter polymorphisms in patients with
type I diabetes showed an increased frequency of IL18
-607 CA genotype compared with control subjects, but
no significant difference in the IL18 -137 allele frequen-
cies [57]. No significant association was found when the
IL18 -137 G>C (rs187238) and the IL18 -607 C>A
(rs1946518) gene polymorphisms were studied in
patients with multiple sclerosis, Crohn disease, or
ulcerative colitis [50,58].
In keeping with the results derived from a study on
Spanish individuals diagnosed with rheumatoid arthritis
(RA) [59], in the present study, we did not find a signifi-
cant association between the IL18 -137 (rs187238) poly-
morphism and biopsy-proven GCA.
A protective effect mediated by the IL18 -607 A/A
genotype was observed in Asian patients with RA [43].
It was not the case for Spanish individuals with RA [59].
However, according to our results, an association exists
between biopsy-proven GCA and the IL18 -607
(rs1946518) gene polymorphism. Moreover, our data
show an additional association of biopsy-proven GCA
with IL18 -1297 T>C (rs360719).
Taken together, the different results in terms of dis-
ease susceptibility mediated by the IL18 gene poly-
morphisms in different autoimmune diseases support
the notion that different pathogenic mechanisms are
involved in the development of polygenic diseases.
Although our data show a clear association of these
polymorphisms with GCA susceptibility in the Spanish
population, further studies in other populations with dif-
ferent genetic backgrounds are needed to clarify fully
the implication of IL18 promoter polymorphisms in
GCA susceptibility. However, most genetic associations
reported in Spanish patients with GCA also have been
replicated in other populations, such as HLA-DRB1 in
North American [16,17], Danish [21], French [60], and
Swiss [61], and IL-6 promoter and eNOS polymorph-
isms, in Italians [24,28]. This evidence may indicate a
high reproducibility of the genetic associations with
GCA among different populations and that the potential
association with IL18 may be also found in other popu-
lations. Nevertheless, the lack of genome-wide associa-
tion studies or whole-genome-scan linkage studies in
GCA makes necessary an independent replication study
to confirm our results by using a population of a differ-
ent genetic background.
When we determined the joint effect of the risk alleles
of IL18 and TLR4, we observed a considerably increased
risk of GCA (OR, 3.7) for those 25% GCA patients who
carried three or more risk alleles compared with those
who carried none. Interestingly, this OR was higher
than that obtained for any IL18 or TLR4 SNPs individu-
ally (OR, 1.37 for IL18 -607; OR, 1.48 for IL18 -1297,
and OR, 1.65 for TLR4 +896 G allele). The additive
effect observed between IL18 and TLR4 suggests that
combining information from common risk polymorph-
isms could improve disease prediction. These observa-
tions, as well as the findings showing that IL18 and
TLR4 genetic variants are associated with other autoim-
mune diseases [33,39-41,50,52,62-64], support the pivo-
t a lr o l eo fi n n a t ei m m u n i t yi nt h ed e v e l o p m e n to f
autoimmunity and GCA. Nevertheless, further studies in
other populations are required to validate our findings.
Conclusions
The present study shows for the first time that IL18
gene promoter polymorphisms are associated with sus-
ceptibility to biopsy-proven GCA. In addition, an addi-
tive effect between the risk IL18 and TLR4 alleles was
observed.
Additional file 1: Supplementary table. Distribution of IL18/TLR4
genotype combinations in GCA patients and controls.
Abbreviations
CI: confidence interval; GCA: giant cell arteritis; IL18: interleukin 18; OR: odds
ratio; SNP: single-nucleotide polymorphism; TLR4: Toll-like receptor 4.
Acknowledgements
We thank Sofia Vargas and Gema Robledo for their invaluable contribution
in the collection, isolation, and storage of the DNA samples. We also thank
Sara Abel Liz, Maria Soledad Folgosa Rodriguez, and Ana Maria Ramos
Gandoy, nurses from the Rheumatology Division (Hospital Xeral-Calde, Lugo,
Spain) for their valuable help in the collection of samples. This study was
supported by a grant from Fondo de Investigaciones Sanitarias PI06-0024
(Spain) and in part by Junta de Andalucía, grupo CTS-180 (Spain). This work
was partially supported by the RETICS Program, RD08/0075 (RIER), from
Instituto de Salud Carlos III (ISCIII).
Author details
1Instituto de Parasitología y Biomedicina Lopez-Neyra, CSIC, Parque
Tecnológico de Ciencias de la Salud, Avenida del Conocimiento s/n Armilla,
Granada-18100, Spain.
2Division of Rheumatology, Hospital Xeral-Calde, c/Dr.
Ochoa, Lugo 27004, Spain.
3Rheumatology Service, Hospital Clínico San
Carlos, c/Profesor Martín Lagos, S/N Madrid - 28040, Spain.
4Department of
Rheumatology, Hospital de la Princesa, Universidad Autónoma, c/Diego de
Palomino-Morales et al. Arthritis Research & Therapy 2010, 12:R51
http://arthritis-research.com/content/12/2/R51
Page 5 of 7León 62, Madrid, 28006, Spain.
5Department of Internal Medicine, Hospital
Clínico San Cecílio, Avenida Doctor Olóriz 16 Granada 18012, Spain.
6Division
of Rheumatology, Hospital Universitario Marques de Valdecilla, Santander-
39008, Spain.
Authors’ contributions
RPM carried out genotyping, participated in the design of the study, data
analysis, and helped to draft the manuscript. TRV participated in the
acquisition and interpretation of data and in the design of the study. OT
participated in the acquisition and interpretation of data. ICM participated in
the acquisition and interpretation of data. SC has been involved in the
acquisition and interpretation of data and in revising it critically for
important intellectual content. JAM participated in the acquisition and
interpretation of data. JLC participated in the acquisition and interpretation
of data. BF has been involved in the acquisition and interpretation of data
and in revising it critically for important intellectual content. MAG-G made
substantial contributions to the conception and design of the study,
acquisition of data, coordination, helped to draft the manuscript, and gave
final approval of the version to be published. JM made substantial
contributions to the conception and design of the study, acquisition of data,
and coordination, helped to draft the manuscript, and gave final approval of
the version to be published.
Competing interests
The authors declare that they have no competing interests.
Received: 10 September 2009 Revised: 2 March 2010
Accepted: 23 March 2010 Published: 23 March 2010
References
1. Salvarani C, Cantini F, Boiardi L, Hunder GG: Polymyalgia rheumatica and
giant-cell arteritis. N Engl J Med 2002, 347:261-271.
2. Gonzalez-Gay MA, Garcia-Porrua C: Epidemiology of the vasculitides.
Rheum Dis Clin North Am 2001, 27:729-749.
3. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, Miranda-Filloy JA,
Gonzalez-Juanatey C, Martin J, Llorca J: Epidemiology of giant cell arteritis
and polymyalgia rheumatica. Arthritis Rheum 2009, 61:1454-1461.
4. Weyand CM, Ma-Krupa W, Pryshchep O, Gröschel S, Bernardino R,
Goronzy JJ: Vascular dendritic cells in giant cell arteritis. Ann N Y Acad Sci
2005, 1062:195-208.
5. Weyand CM, Goronzy JJ: The Dunlop-Dottridge Lecture: the pathogenesis
of giant cell arteritis. J Rheumatol 2000, 27:517-522.
6. Gracie JA, Robertson SE, McInnes IB: Interleukin-18. J Leukoc Biol 2003,
73:213-224.
7. McInnes IB, Gracie JA, Leung BP, Wei XQ, Liew FY: Interleukin 18: a
pleiotropic participant in chronic inflammation. Immunol Today 2000,
21:312-315.
8. Dinarello CA: Interleukin-18. Methods 1999, 19:121-132.
9. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H: Interleukin-18 regulates
both Th1 and Th2 responses. Annu Rev Immunol 2001, 19:423-474.
10. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H: Interleukin-18 is a unique
cytokine that stimulates both Th1 and Th2 responses depending on its
cytokine milieu. Cytokine Growth Factor Rev 2001, 12:53-72.
11. Yoshimoto T, Takeda K, Tanaka T, Ohkusu K, Kashiwamura S, Okamura H,
Akira S, Nakanishi K: IL-12 up-regulates IL-18 receptor expression on T
cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma
production. J Immunol 1998, 161:3400-3407.
12. Tominaga K, Yoshimoto T, Torigoe K, Kurimoto M, Matsui K, Hada T,
Okamura H, Nakanishi K: IL-12 synergizes with IL-18 or IL-1beta for IFN-
gamma production from human T cells. Int Immunol 2000, 12:151-160.
13. Yoshimoto T, Mizutani H, Tsutsui H, Noben-Trauth N, Yamanaka K,
Tanaka M, Izumi S, Okamura H, Paul WE, Nakanishi K: IL-18 induction of
IgE: dependence on CD4+ T cells, IL-4 and STAT6. Nat Immunol 2000,
1:132-137.
14. Yoshimoto T, Tsutsui H, Tominaga K, Hoshino K, Okamura H, Akira S,
Paul WE, Nakanishi K: IL-18, although antiallergic when administered with
IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad
Sci USA 1999, 96:13962-13966.
15. Gonzalez-Gay MA, Amoli MM, Garcia-Porrua C, Ollier WE: Genetic markers
of disease susceptibility and severity in giant cell arteritis and
polymyalgia rheumatica. Semin Arthritis Rheum 2003, 33:38-48.
16. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ: The HLA-DRB1 locus as a
genetic component in giant cell arteritis: mapping of a disease-linked
sequence motif to the antigen binding site of the HLA-DR molecule.
J Clin Invest 1992, 90:2355-2361.
17. Weyand CM, Hunder NN, Hicok KC, Hunder GG, Goronzy JJ: HLA-DRB1
alleles in polymyalgia rheumatica, giant cell arteritis, and rheumatoid
arthritis. Arthritis Rheum 1994, 37:514-520.
18. Dababneh A, Gonzalez-Gay MA, Garcia-Porrua C, Hajeer A, Thomson W,
Ollier W: Giant cell arteritis and polymyalgia rheumatica can be
differentiated by distinct patterns of HLA class II association. J Rheumatol
1998, 25:2140-2145.
19. Mattey DL, Hajeer AH, Dababneh A, Thomson W, González-Gay MA, García-
Porrúa C, Ollier WE: Association of giant cell arteritis and polymyalgia
rheumatica with different tumor necrosis factor microsatellite
polymorphisms. Arthritis Rheum 2000, 43:1749-1755.
20. Gonzalez-Gay MA, Rueda B, Vilchez JR, Lopez-Nevot MA, Robledo G,
Ruiz MP, Fernández O, Garcia-Porrua C, Gonzalez-Escribano MF, Martín J:
Contribution of MHC class I region to genetic susceptibility for giant cell
arteritis. Rheumatology 2007, 46:431-434.
21. Jacobsen S, Baslund B, Madsen HO, Tvede N, Svejgaard A, Garred P:
Mannose-binding lectin variant alleles and HLA-DR4 alleles are
associated with giant cell arteritis. J Rheumatol 2002, 29:2148-21453.
22. Gonzalez-Gay MA, Hajeer AH, Dababneh A, Garcia-Porrua C, Amoli MM,
Llorca J, Ollier WE: Interferon-gamma gene microsatellite polymorphisms
in patients with biopsy-proven giant cell arteritis and isolated
polymyalgia rheumatica. Clin Exp Rheumatol 2004, 22(6 Suppl 36):S18-S20.
23. Gonzalez-Gay MA, Hajeer AH, Dababneh A, Garcia-Porrua C, Mattey DL,
Amoli MM, Thomson W, Ollier WE: IL-6 promoter polymorphism at
position -174 modulates the phenotypic expression of polymyalgia
rheumatica in biopsy-proven giant cell arteritis. Clin Exp Rheumatol 2002,
20:179-184.
24. Salvarani C, Casali B, Farnetti E, Pipitone N, Nicoli D, Macchioni P, Cimino L,
Bajocchi G, Catanoso MG, Boiardi L: Interleukin-6 promoter polymorphism
at position -174 in giant cell arteritis. J Rheumatol 2005, 32:2173-2177.
25. Boiardi L, Casali B, Farnetti E, Pipitone N, Nicoli D, Macchioni P, Cimino L,
Bajocchi G, Catanoso MG, Pattacini L, Salvarani C: Interleukin-10 promoter
polymorphisms in giant cell arteritis. Arthritis Rheum 2006, 54:4011-4017.
26. Rueda B, Roibas B, Martin J, Gonzalez-Gay MA: Influence of interleukin 10
promoter polymorphisms in susceptibility to giant cell arteritis in
Northwestern Spain. J Rheumatol 2007, 34:1535-1539.
27. Salvarani C, Casali B, Boiardi L, Ranzi A, Macchioni P, Nicoli D, Farnetti E,
Brini M, Portioli I: Intercellular adhesion molecule 1 gene polymorphisms
in polymyalgia rheumatica/giant cell arteritis: association with disease
risk and severity. J Rheumatol 2000, 27:1215-1221.
28. Salvarani C, Casali B, Nicoli D, Farnetti E, Macchioni P, Catanoso MG,
Chen Q, Bajocchi G, Boiardi L: Endothelial nitric oxide synthase gene
polymorphisms in giant cell arteritis. Arthritis Rheum 2003, 48:3219-3223.
29. Amoli MM, Garcia-Porrua C, Llorca J, Ollier WE, Gonzalez-Gay MA:
Endothelial nitric oxide synthase haplotype associations in biopsy-
proven giant cell arteritis. J Rheumatol 2003, 30:2019-2022.
30. Gonzalez-Gay MA, Oliver J, Sanchez E, Garcia-Porrua C, Paco L, Lopez-
Nevot MA, Ollier WE, Martin J: Association of a functional inducible nitric
oxide synthase promoter variant with susceptibility to biopsy-proven
giant cell arteritis. J Rheumatol 2005, 32:2178-2182.
31. Rueda B, Lopez-Nevot MA, Lopez-Diaz MJ, Garcia-Porrua C, Martín J,
Gonzalez-Gay MA: A functional variant of vascular endothelial growth
factor is associated with severe ischemic complications in giant cell
arteritis. J Rheumatol 2005, 32:1737-1741.
32. Morgan AW, Robinson JI, Barrett JH, Martin J, Walker A, Babbage SJ,
Ollier WE, Gonzalez-Gay MA, Isaacs JD: Association of FCGR2A and
FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis.
Arthritis Res Ther 2006, 8:R109.
33. Rueda B, Miranda-Filloy JA, Martin J, Gonzalez-Gay MA: Association of
CD24 gene polymorphisms with susceptibility to biopsy-proven giant
cell arteritis. J Rheumatol 2008, 35:850-854.
34. Rodríguez-Pla A, Beaty TH, Savino PJ, Eagle RC Jr, Seo P, Soloski MJ:
Association of a nonsynonymous single-nucleotide polymorphism of
matrix metalloproteinase 9 with giant cell arteritis. Arthritis Rheum 2008,
58:1849-1853.
Palomino-Morales et al. Arthritis Research & Therapy 2010, 12:R51
http://arthritis-research.com/content/12/2/R51
Page 6 of 735. Nolan KF, Greaves DR, Waldmann H: The human interleukin 18 gene IL18
maps to 11q22.2-q22.3, closely linked to the DRD2 gene locus and
distinct from mapped IDDM loci. Genomics 1998, 51:161-163.
36. Higa S, Hirano T, Mayumi M, Hiraoka M, Ohshima Y, Nambu M,
Yamaguchi E, Hizawa N, Kondo N, Matsui E, Katada Y, Miyatake A, Kawase I,
Tanaka T: Association between interleukin-18 gene polymorphism 105A/
C and asthma. Clin Exp Allergy 2003, 33:1097-1102.
37. Imboden M, Nicod L, Nieters A, Glaus E, Matyas G, Bircher AJ, Ackermann-
Liebrich U, Berger W, Probst-Hensch NM, SAPALDIA Team: The common G-
allele of interleukin-18 single-nucleotide polymorphism is a genetic risk
factor for atopic asthma: The SAPALDIA Cohort Study. Clin Exp Allergy
2006, 36:211-218.
38. Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, Schnabel R,
Bickel C, Espinola-Klein C, Poirier O, Perret C, Münzel T, Rupprecht HJ,
Lackner K, Cambien F, Blankenberg S, Athero Gene Investigators: Genetic
analysis of the interleukin-18 system highlights the role of the
interleukin-18 gene in cardiovascular disease. Circulation 2005,
112:643-650.
39. Kretowski A, Mironczuk K, Karpinska A, Bojaryn U, Kinalski M, Puchalski Z,
Kinalska I: Interleukin-18 promoter polymorphisms in type 1 diabetes.
Diabetes 2002, 51:3347-3349.
40. Mojtahedi Z, Naeimi S, Farjadian S, Omrani GR, Ghaderi A: Association of
IL-18 promoter polymorphisms with predisposition to Type 1 diabetes.
Diabet Med 2006, 23:235-239.
41. Sugiura T, Maeno N, Kawaguchi Y, Takei S, Imanaka H, Kawano Y, Terajima-
Ichida H, Hara M, Kamatani N: A promoter haplotype of the interleukin-18
gene is associated with juvenile idiopathic arthritis in the Japanese
population. Arthritis Res Ther 2006, 8:R60.
42. Tamura K, Fukuda Y, Sashio H, Takeda N, Bamba H, Kosaka T, Fukui S,
Sawada K, Tamura K, Satomi M, Yamada T, Yamamura T, Yamamoto Y,
Furuyama J, Okamura H, Shimoyama T: IL18 polymorphism is associated
with an increased risk of Crohn’s disease. J Gastroenterol 2002, 37:111-116.
43. Sivalingam SP, Yoon KH, Koh DR, Fong KY: Single-nucleotide
polymorphisms of the interleukin-18 gene promoter region in
rheumatoid arthritis patients: protective effect of AA genotype. Tissue
Antigens 2003, 62:498-504.
44. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH,
Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, Masi AT, et al:
The American College of Rheumatology 1990 criteria for the
classification of giant cell arteritis. Arthritis Rheum 1990, 33:1122-8.
45. Gonzalez-Gay MA, Garcia-Porrua C, Llorca J, Gonzalez-Louzao C, Rodriguez-
Ledo P: Biopsy-negative giant cell arteritis: clinical spectrum and
predictive factors for positive temporal artery biopsy. Semin Arthritis
Rheum 2001, 30:249-256.
46. Palomino-Morales R, Torres O, Vazquez-Rodriguez TR, Morado IC,
Castañeda S, Callejas-Rubio JL, Miranda-Filloy JA, Fernandez-Gutierrez B,
Martin J, Gonzalez-Gay MA: Association between Toll-like receptor 4 gene
polymorphism and biopsy-proven giant cell arteritis. J Rheumatol 2009,
36:1501-1506.
47. Gonzalez-Gay MA, Garcia-Porrua C, Vazquez-Caruncho M: Polymyalgia
rheumatica in biopsy proven giant cell arteritis does not constitute a
different subset but differs from isolated polymyalgia rheumatica. J
Rheumatol 1998, 25:1750-1755.
48. Gonzalez-Gay MA, Pineiro A, Gomez-Gigirey A, Garcia-Porrua C, Pego-
Reigosa R, Dierssen-Sotos T, Llorca J: Influence of traditional risk factors of
atherosclerosis in the development of severe ischemic complications in
giant cell arteritis. Medicine (Baltimore) 2004, 83:342-347.
49. Tone M, Thompson SA, Tone Y, Fairchild PJ, Waldmann H: Regulation of IL-
18 (IFN-gamma-inducing factor) gene expression. J Immunol 1997,
159:6156-6163.
50. Giedraitis V, He B, Huang WX, Hillert J: Cloning and mutation analysis of
the human IL-18 promoter: a possible role of polymorphisms in
expression regulation. J Neuroimmunol 2001, 112:146-152.
51. PubMed. [http://www.ncbi.nlm.nih.gov/sites/entrez].
52. Sánchez E, Palomino-Morales RJ, Ortego-Centeno N, Jiménez-Alonso J,
González-Gay MA, López-Nevot MA, Sánchez-Román J, de Ramón E,
González-Escribano MF, Pons-Estel BA, D’Alfonso S, Sebastiani GD, Italian
collaborative group, Alarcón-Riquelme ME, Martín J: Identification of a new
putative IL18 gene variant through a functional and association study in
systemic lupus erythematosus. Hum Mol Genet 2009, 18:3739-3748.
53. Weyand CM, Hicok KC, Hunder GG, Goronzy JJ: Tissue cytokine patterns in
patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern
Med 1994, 121:484-491.
54. Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, Garcia-Porrua C, Sanchez-
Andrade A, Paz-Carreira J, Martin J, Llorca J: Giant cell arteritis: laboratory
tests at the time of diagnosis in a series of 240 patients. Medicine
(Baltimore) 2005, 84:277-290.
55. Thompson SR, Humphries SE: Interleukin-18 genetics and inflammatory
disease susceptibility. Genes Immun 2007, 8:91-99.
56. Nabili S, Bhatt P, Roberts F, Gracie A, McFadzean R: Local expression of IL-
18 in the temporal artery does not correlate with clinical manifestations
of giant cell arteritis. Neuro-Ophthalmology 2008, 32:3-6.
57. Ide A, Kawasaki E, Abiru N, Sun F, Kobayashi M, Fukushima T, Takahashi R,
Kuwahara H, Kita A, Oshima K, Uotani S, Yamasaki H, Yamaguchi Y,
Eguchi K: Association between IL-18 gene promoter polymorphisms and
CTLA-4 gene 49A/G polymorphism in Japanese patients with type 1
diabetes. J Autoimmun 2004, 22:73-78.
58. Glas J, Torok HP, Tonenchi L, Kapser J, Schiemann U, Muller-Myhsok B,
Folwaczny M, Folwaczny C: Association of polymorphisms in the
interleukin-18 gene in patients with Crohn’s disease depending on the
CARDIS15/NOD2 genotype. Inflamm Bowel Dis 2005, 11:1031-1037.
59. Rueda B, González-Gay MA, Matarán L, López-Nevot MA, Martín J:
Interleukin-18-promoter polymorphisms are not relevant in rheumatoid
arthritis. Tissue Antigens 2005, 65:544-548.
60. Rauzy O, Fort M, Nourhashemi F, Alric L, Juchet H, Ecoiffier M, Abbal M,
Adoue D: Relation between HLA DRB1 alleles and corticosteroid
resistance in giant cell arteritis. Ann Rheum Dis 1998, 57:380-382.
61. Guerne PA, Salvi M, Seitz M, Bruhlmann P, Rivier G, Frey D, Mermillod B,
Vischer TL, Tiercy JM: Molecular analysis of HLA-DR polymorphism in
polymyalgia rheumatica: Swiss Group for Research on HLA in
Polymyalgia Rheumatica. J Rheumatol 1997, 24:671-676.
62. Radstake TR, Franke B, Hanssen S, Netea MG, Welsing P, Barrera P,
Joosten LA, van Riel PL, Berg van den WB: The Toll-like receptor 4
Asp299Gly functional variant is associated with decreased rheumatoid
arthritis disease susceptibility but does not influence disease severity
and/or outcome. Arthritis Rheum 2004, 50:999-1001.
63. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T,
Quertinmont E, Abramowicz M, Van Gossum A, Devière J, Rutgeerts P:
Deficient host-bacteria interactions in inflammatory bowel disease? The
Toll-like receptor (TLR)-4 Asp299 gly polymorphism is associated with
Crohn’s disease and ulcerative colitis. Gut 2004, 53:987-992.
64. Pierangeli SS, Vega-Ostertag ME, Raschi E, Liu X, Romay-Penabad Z, De
Micheli V, Galli M, Moia M, Tincani A, Borghi MO, Nguyen-Oghalai T,
Meroni PL: Toll-like receptor and antiphospholipid mediated thrombosis:
in vivo studies. Ann Rheum Dis 2007, 66:1327-1333.
doi:10.1186/ar2962
Cite this article as: Palomino-Morales et al.: Association between IL-18
gene polymorphisms and biopsy-proven giant cell arteritis. Arthritis
Research & Therapy 2010 12:R51.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Palomino-Morales et al. Arthritis Research & Therapy 2010, 12:R51
http://arthritis-research.com/content/12/2/R51
Page 7 of 7